Prometic and SRAM JV to develop and commercialise three drug candidates in China
Pharmaceutical Technology | March 31, 2017
Prometic Life Sciences has signed a memorandum of terms with Shenzhen Royal Asset Management (SRAM) to establish a joint venture (JV) for the development, manufacture and commercialisation of three drug candidates, PBI-4050, PBI-4547 and PBI-4425, in China.